ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum.

Apolipoprotein (apo) E-deficient transgenic mice develop marked hyperlipidemia and progressive atherosclerotic lesions. To explore whether oxidative modification of lipoproteins is involved in atherogenesis in this murine model, we performed extensive immunocytochemical studies. Atherosclerotic lesions ranging from early fatty streaks to very advanced plaques were examined from the aortic valve region and the thoracic and abdominal aorta. Using guinea pig antisera against malondialdehyde (MDA)-lysine and 4-hydroxynonenal-lysine, two epitopes generated during the oxidative modification of low-density lipoprotein (LDL), we demonstrated the presence of these "oxidation-specific epitopes" in atherosclerotic lesions. In early lesions, oxidation-specific epitopes were found predominantly in macrophage-rich areas, whereas diffuse extracellular staining predominated in necrotic areas of advanced lesions. We have previously shown that autoantibodies against MDA-lysine are present in the circulation of humans and rabbits and that the immunoglobulin fraction extracted from their lesions contains autoantibodies against several "oxidation-specific" epitopes. Sera from apoE-deficient mice also contained circulating autoantibodies to MDA-lysine, and both early and advanced lesions were rich in murine immunoglobulins. Titers of serum autoantibodies were significantly higher in apoE-deficient mice than in C57BL/6 mice. Autoantibodies in murine plasma recognized MDA-lysine epitopes in atherosclerotic lesions of rabbits, and the immunostaining was competitively inhibited by excess human MDA-LDL. Similar findings were obtained by competitive radioimmunoassay. Finally, a morphometric technique was developed and tested in these mice that allows a quantitative assessment of aortic atherosclerosis. These findings suggest that in apoE-deficient mice, lipoprotein oxidation is involved in atherogenesis and that these transgenic mice constitute an appropriate model with which to study the antiatherogenic effect of antioxidant intervention.

[1]  M. Mitchell,et al.  Pre-eclampsia and serum antibodies to oxidised low-density lipoprotein , 1994, The Lancet.

[2]  J. Breslow.  Transgenic mouse models of lipoprotein metabolism and atherosclerosis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  V. Ord,et al.  Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[4]  J. Witztum.  Murine models for study of lipoprotein metabolism and atherosclerosis. , 1993, The Journal of clinical investigation.

[5]  R. Hammer,et al.  Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.

[6]  D. Steinberg,et al.  Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. , 1993, The Journal of clinical investigation.

[7]  J. Qiao,et al.  Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. , 1993, Science.

[8]  K. Marotti,et al.  Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein , 1993, Nature.

[9]  R. Frants,et al.  Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. , 1993, The Journal of biological chemistry.

[10]  N. Mackman,et al.  Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. , 1993, The Journal of clinical investigation.

[11]  M. Brown,et al.  Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. , 1992, The Journal of biological chemistry.

[12]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[13]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[14]  Margaret S. Wu,et al.  Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. , 1992, The Journal of clinical investigation.

[15]  J. Salonen,et al.  Autoantibody against oxidised LDL and progression of carotid atherosclerosis , 1992, The Lancet.

[16]  P. Libby,et al.  Increased apolipoprotein E and c-fms gene expression without elevated interleukin 1 or 6 mRNA levels indicates selective activation of macrophage functions in advanced human atheroma. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Giscombe,et al.  Induction of T-cell activation by oxidized low density lipoprotein. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[18]  H F Hoff,et al.  Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[19]  P. Henriksson,et al.  The antioxidant butylated hydroxytoluene protects against atherosclerosis. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[20]  P. Libby,et al.  Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[21]  D. Steinberg,et al.  Role of oxidised low density lipoprotein in atherogenesis. , 1993, British heart journal.

[22]  S. Ylä-Herttuala,et al.  Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. , 1990, Arteriosclerosis.

[23]  J L Witztum,et al.  Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. , 1990, Arteriosclerosis.

[24]  J. Ordovás,et al.  Induction of apolipoprotein E gene expression in human and experimental atherosclerotic lesions. , 1990, Biochemical and biophysical research communications.

[25]  A. Lusis,et al.  Phenotypic characterization of the Ath-1 gene controlling high density lipoprotein levels and susceptibility to atherosclerosis. , 1990, Journal of lipid research.

[26]  A. Gown,et al.  Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. , 1989, The American journal of pathology.

[27]  J L Witztum,et al.  Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. , 1989, The Journal of clinical investigation.

[28]  G. Hansson,et al.  Detection of activated T lymphocytes in the human atherosclerotic plaque. , 1989, The American journal of pathology.

[29]  G. Hansson,et al.  Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[30]  B. Paigen,et al.  Ath-2, a second gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. , 1989, Genetics.

[31]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[32]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Haberland,et al.  Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. , 1988, Science.

[34]  R. Mahley,et al.  Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.

[35]  R. Hammer,et al.  Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice. , 1988, Science.

[36]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Lusis,et al.  Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Steinberg,et al.  Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Badimón,et al.  Quantification and immunolocalization of apolipoprotein E in experimental atherosclerosis. , 1986, Atherosclerosis.

[41]  S. Ishibashi,et al.  Immunohistochemical localization of apolipoprotein E in atherosclerotic lesions of the aorta and coronary arteries. , 1986, Atherosclerosis.

[42]  R. Mahley,et al.  Apolipoprotein E Is the Determinant that Mediates the Receptor Uptake of B‐Very Low Density Lipoproteins by Mouse Macrophages , 1986, Arteriosclerosis.

[43]  H. Rus,et al.  Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. , 1985, Atherosclerosis.

[44]  G. Gabbiani,et al.  Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. , 1985, The Journal of clinical investigation.

[45]  J. Witztum,et al.  Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. , 1984, Journal of lipid research.

[46]  R. Havel,et al.  Mouse macrophages synthesize and secrete a protein resembling apolipoprotein E. , 1981, Proceedings of the National Academy of Sciences of the United States of America.